Recently, Kamal and coworkers have found that MLKL is associated to hallmarks of atherosclerosis with and without type II diabetes mellitus, which could be a potential drug target for treating atherosclerotic patients [50]. The gene discussed is MLKL; the disease is type 2 diabetes mellitus.